Roche To Strengthen R&D Pipeline In Israel
Company to initially focus on early-stage biotech
Roche has sealed a deal with Pontifax Management to build a R&D pipeline in Israel. Under the agreement, Pontifax will help Roche to identify and invest in Israeli biotech companies. The company will initially focus on early-stage biotech firms foccused on drug development, clinical trials, manufacturing and marketing.
Selected start-ups will be admitted to an incubator affiliated with Pontifax. The joint investment will complement funding through the incubator program of the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor.
Roche is a healthcare process company focused on identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring.
Herzliya-based Pontifax specializes in investments in seed, early and mid stage companies, including startups.
Related Insight
Suppliers Directory
IRW - Full-Service Nordic Clinical Research Organisation (CRO)
IRW is a Nordic full-service Clinical Research Organisation (CRO) with more than ten years experience and local offices in Sweden, Denmark, Finland and Norway. We offer solid know-how and experience of clinical research, data management, biostatistics and pharmacovigilance for global and small pharma, biotech and the medical devices industry.
Suppliers
Boehringer Ingelheim - Drug Substance and Drug Product Services
Boehringer Ingelheim Pharma Chemicals is your development, launch and post-launch partner for your small-molecule Active Pharmaceutical Ingredients (APIs) and dosage forms (Drug Products).
Suppliers
Pharmatest Services - Preclinical Contract Research
Pharmatest Services Ltd is a full-service bone biology CRO specialised in preclinical testing of new drug candidates both in vitro and in vivo. We provide cost-effective solutions for fast and high quality preclinical drug efficacy research.
Suppliers
PharmARC - Analytic Solutions for Efficient Commercialisation of Drugs and Medical Products
PharmARC is a 100% life sciences focused company that provides analytic solutions for efficient commercialization of drugs and medical products. We enable our customers to make informed decisions related to their sales and marketing strategies, and implementation, yielding better ROI.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Transforming Randomization and Trial Supply Management
Published by Medidata Solutions
White Papers
State and Federal “Sunshine Acts” Shift KOL Marketing Tactics
Published by Alliance Life Sciences Consulting Group, Inc.
White Papers
SynBiosys™ Drug Delivery Systems
Published by InnoCore Technologies BV
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.